4//SEC Filing
Neumann Mark 4
Accession 0000950170-25-036592
CIK 0001567514other
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 6:01 PM ET
Size
13.7 KB
Accession
0000950170-25-036592
Insider Transaction Report
Form 4
Neumann Mark
EVP, Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-06+13,133→ 54,154 total - Tax Payment
Common Stock
2025-03-06$131.19/sh−5,572$730,991→ 48,582 total - Exercise/Conversion
Restricted Stock Units
2025-03-10−7,345→ 0 total→ Common Stock (7,345 underlying) - Exercise/Conversion
Restricted Stock Units
2025-03-06−13,133→ 13,133 total→ Common Stock (13,133 underlying) - Tax Payment
Common Stock
2025-03-10$131.24/sh−3,116$408,944→ 52,811 total - Exercise/Conversion
Common Stock
2025-03-10+7,345→ 55,927 total
Footnotes (5)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person.
- [F3]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F4]On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F5]On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Documents
Issuer
Intra-Cellular Therapies, Inc.
CIK 0001567514
Entity typeother
Related Parties
1- filerCIK 0001756211
Filing Metadata
- Form type
- 4
- Filed
- Mar 9, 8:00 PM ET
- Accepted
- Mar 10, 6:01 PM ET
- Size
- 13.7 KB